

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

**(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON OCTOBER 25, 2024**
**(2) APPOINTMENT OF DIRECTORS OF
THE SECOND SESSION OF THE BOARD**
**(3) APPOINTMENT OF NON-EMPLOYEE REPRESENTATIVE SUPERVISORS
OF THE SECOND SESSION OF THE SUPERVISORY COMMITTEE**
**(4) ELECTION OF THE CHAIRMAN OF THE SECOND SESSION OF
THE BOARD AND MEMBERS OF SPECIAL COMMITTEES**
**(5) ELECTION OF THE CHAIRMAN OF THE SECOND SESSION OF
THE SUPERVISORY COMMITTEE**
AND
(6) RE-APPOINTMENT OF GENERAL MANAGER

According to the announcement dated September 24, 2024 (the “**Announcement**”), the notice of EGM dated September 30, 2024 (the “**Notice**”), and the circular dated September 30, 2024 (the “**Circular**”) of the extraordinary general meeting (the “**EGM**”) of Qyuns Therapeutics Co., Ltd. (the “**Company**”), the EGM of the Company was held at North Conference Room, 2nd Floor, Building 1, No. 907 Yaocheng Avenue, Taizhou City, Jiangsu Province, the PRC on Friday, October 25, 2024 at 2:00 p.m. Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as given to them in the Announcement, the Notice and the Circular.

The total number of the issued shares of the Company as at the date of the EGM was 222,071,600 shares, of which 17,322,400 shares were unlisted shares and 204,749,200 shares were H shares. Accordingly, the total number of shares entitling the holders to attend and vote for or against any of the proposed resolutions at the EGM was 222,071,600 shares.

As at the date of the EGM, Zhongmei Huadong held 35,900,000 shares of the Company, representing approximately 16.17% of the issued share capital of the Company. Huadong Investment, which is wholly-owned by Huadong Medicine, held 1,976,800 shares of the Company, representing approximately 0.89% of the issued share capital of the Company. Accordingly, Zhongmei Huadong and Huadong Investment are required to abstain from voting on the resolution to approve the Cooperation Agreement at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”). None of the Shareholders of the Company has stated his or her intention in the Circular to vote against or abstain from voting on any resolutions at the EGM.

As far as the Directors are aware, having made all reasonable enquiries, save as disclosed above, no other Shareholders are required to abstain from voting on the resolutions referred to above at the EGM.

The number of Shareholders and proxies attending the EGM was 3. The Shareholders and proxies attending the EGM in respect of resolution numbered 1 held a total of 148,232,401 shares with voting rights, representing 80.48% of the total number of shares with voting rights. The Shareholders and proxies attending the EGM in respect of resolutions numbered 2 to 12 held a total of 186,109,201 shares with voting rights, representing 83.81% of the total number of shares with voting rights.

The holding of the EGM was in compliance with the requirements of the Company Law of the PRC (《中華人民共和國公司法》) and the Articles of Association of the Company.

Tricor Investor Services Limited, the Company's H share registrar, acted as the scrutineer for the vote-taking at the EGM.

The following Directors of the Company attended the EGM: Mr. Qiu Jiwan, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors; Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive Directors; and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.

VOTING RESULTS OF THE EGM

At the EGM of the Company held on October 25, 2024, all the proposed resolutions as set out in the Notice and the Circular were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the Cooperation Agreement dated July 19, 2024 entered into between the Company and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (杭州中美華東製藥有限公司) (the “Cooperation Agreement”) (including the transactions contemplated thereunder) and the Proposed Annual Caps for each of the three years ending December 31, 2026 as set out in the Circular; and to authorize any Director to exercise all powers which they consider necessary and do such other acts and things and execute such other documents which in their opinion may be necessary or desirable to implement the transactions contemplated under the Cooperation Agreement.	148,232,401 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and, if thought fit, approve the appointment of Mr. Qiu Jiwan as executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
3.	To consider and, if thought fit, approve the appointment of Mr. Wu Yiliang as executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
4.	To consider and, if thought fit, approve the appointment of Mr. Lin Weidong as executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
5.	To consider and, if thought fit, approve the appointment of Mr. Yu Xi as non-executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
6.	To consider and, if thought fit, the appointment of Mr. Wu Zhiqiang as non-executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
7.	To consider and, if thought fit, approve the appointment of Dr. Xue Mingyu as non-executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
8.	To consider and, if thought fit, approve the appointment of Dr. Zou Zhongmei as independent non-executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
9.	To consider and, if thought fit, approve the appointment of Dr. Ling Jianqun as independent non-executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
10.	To consider and, if thought fit, approve the appointment of Mr. Fung Che Wai, Anthony as independent non-executive Directors of the second session of the Board.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
11.	To consider and, if thought fit, approve the appointment of Mr. Ye Xiang as the non-employee representative Supervisors of the second session of the Board of Supervisors.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
12.	To consider and, if thought fit, approve the appointment of Dr. Ding Chao as the non-employee representative Supervisors of the second session of the Board of Supervisors.	186,109,201 (100.00%)	0 (0.00%)	0 (0.00%)
*		As more than half of the votes were cast in favour of each of the resolutions numbered 1 to 12, all resolutions were duly passed as ordinary resolutions.		

APPOINTMENT OF DIRECTORS OF THE SECOND SESSION OF THE BOARD

The Board is pleased to announce that at the EGM, (i) Mr. Qiu Jiwan, Mr. Wu Yiliang and Mr. Lin Weidong were appointed as executive Directors of the second session of the Board; (ii) Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu were appointed as non-executive Directors of the second session of the Board; and (iii) Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony were appointed as independent non-executive Directors of the second session of the Board. Please refer to Appendix II to the Circular for the biographical details of the above appointed Directors and other information disclosed pursuant to Rule 13.51(2) of the Listing Rules. Since September 2023, Mr. Fung Che Wai, Anthony has been serving as an independent non-executive director at Zhejiang Taimei Medical Technology Co., Ltd. (stock code: 2576), which was listed on the Stock Exchange in October 2024. As at the date of this announcement, there has not been any other change in such information. Save as disclosed in the Circular and above, there is no other information relating to the Directors that is required to be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders of the Company.

APPOINTMENT OF NON-EMPLOYEE REPRESENTATIVE SUPERVISORS OF THE SECOND SESSION OF THE SUPERVISORY COMMITTEE

The Board is pleased to announce that at the EGM, Mr. Ye Xiang and Dr. Ding Chao were appointed as non-employee representative Supervisors of the second session of the Supervisory Committee of the Company. Please refer to Appendix III to the Circular for the biographical details of Mr. Ye Xiang and Dr. Ding Chao and other information disclosed pursuant to Rule 13.51(2) of the Listing Rules. As at the date of this announcement, there has not been any change in such information.

ELECTION OF THE CHAIRMAN OF THE SECOND SESSION OF THE BOARD AND MEMBERS OF SPECIAL COMMITTEES

The Board held a Board meeting on October 25, 2024 and elected (i) Mr. Qiu Jiwan as the chairman of the second session of the Board of the Company for a term commencing from the date of consideration and approval by the Board to the end of the term of office of the second session of the Board; (ii) Mr. Fung Che Wai, Anthony, Mr. Wu Zhiqiang and Dr. Ling Jianqun as members of the audit committee of the second session of the Board, with Mr. Fung Che Wai, Anthony as the chairman of the audit committee; (iii) Dr. Ling Jianqun, Dr. Zou Zhongmei and Mr. Qiu Jiwan are members of the remuneration and appraisal committee of the second session of the Board, with Dr. Ling Jianqun as the chairman of the remuneration and appraisal committee; (iv) Mr. Qiu Jiwan, Dr. Zou Zhongmei and Dr. Ling Jianqun as members of the nomination committee of the second session of the Board, with Mr. Qiu Jiwan as the chairman of the nomination committee; and (v) Mr. Qiu Jiwan, Mr. Yu Xi and Dr. Xue Mingyu as members of the strategy and development committee of the second session of the Board, with Mr. Qiu Jiwan as the chairman of the strategy and development committee. The term of office of the members of the aforementioned special committees of the Board shall be the same as their term of office as Directors, commencing from the date of consideration and approval by the Board to the end of the term of office of the second session of the Board.

ELECTION OF THE CHAIRMAN OF THE SECOND SESSION OF THE SUPERVISORY COMMITTEE

The Supervisory Committee held a meeting of the Supervisory Committee on October 25, 2024 and Mr. Ye Xiang (“**Mr. Ye**”) was appointed as the chairman of the second session of the Supervisory Committee of the Company, please refer to Appendix III to the Circular for the biographical details of Mr. Ye. Save as such disclosure, the Board is not aware of any other information relating to Mr. Ye that is required to be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters regarding Mr. Ye that need to be brought to the attention of the Shareholders.

RE-APPOINTMENT OF GENERAL MANAGER

In view of the fact that Mr. Qiu Jiwan’s term of office as the general manager of the Company has expired in September 2024, at the Board meeting held on October 25, 2024, the Board re-appointed Mr. Qiu Jiwan as the general manager of the Company for a term commencing from the date of consideration and approval by the Board to the end of the term of office of the second session of the Board. Please refer to Appendix II to the Circular for the biographical details of Mr. Qiu and other information disclosed pursuant to Rule 13.51(2) of the Listing Rules. As at the date of this announcement, there has not been any change in such information. Save as disclosed in the Circular, the Board is not aware of any other information in relation to the re-appointment of Mr. Qiu as the general manager that is required to be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters regarding the re-appointment of Mr. Qiu as the general manager that need to be brought to the attention of the Shareholders.

According to code provision C.2.1 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, the roles of chairman of the Board and chief executive officer shall be separate and shall not be performed by the same individual at the same time. As the founder of the Company, Mr. Qiu has been the general manager and responsible for the overall management of the Company since the early stage of its establishment and is a seasoned industry player with extensive experience in the industry and corporate management. In view of Mr. Qiu’s experience, personal qualifications and position in the Company, the Board considers that Mr. Qiu’s chairmanship of the Board of the Company and his continued service as the general manager of the Company will be conducive to ensuring the Company’s consistent leadership and more efficient implementation of the Company’s overall strategic plan.

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, October 25, 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.